Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | RAF1 | P04049 | 4/20 | 0.32 |
| ▸ | BRAF | P15056 | 4/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729802 | 0.83 | PIK3CA (0.35) | PIK3CAMAPK14KDM4EKMT2AMEN1 | |
| SCHEMBL22729527 | 0.78 | RET (0.34) | PIK3CAMAPK14RAF1BRAFKMT2A | |
| SCHEMBL22755188 | 0.70 | PIK3CA (0.34) | PIK3CAMAPK14RAF1KMT2A | |
| SCHEMBL22729595 | 0.68 | BRD4 (0.58) | KDM4EHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL22729400 | 0.68 | BCAT2 (0.38) | EIF4EBP1KMT2AMEN1LMNA | |
| SCHEMBL22729775 | 0.68 | MAP2K1 (0.43) | MAPK14KDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL22729749 | 0.65 | ADORA2A (0.44) | KDM4EHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL29839384 | 0.65 | ADORA2A (0.44) | KDM4EHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL27199691 | 0.65 | BCAT2 (0.35) | KMT2AMEN1LMNA | |
| SCHEMBL2826090 | 0.62 | ALDH1A1 (0.34) | NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | PIK3CA 1514/4885MAPK14 1506/4885RAF1 3726/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | PIK3CA 1435/4885MAPK14 1556/4885RAF1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.